| deCODE Genetics ehf. Patent applications |
| Patent application number | Title | Published |
|---|
| 20120264636 | GENETIC VARIANTS INDICATIVE OF VASCULAR CONDITIONS - The invention relates to procedures and methods of determining a susceptibility to certain vascular conditions, including Atrial Fibrillation, Atrial Flutter and Stroke, by assessing the presence or absence of alleles at polymorphic markers found to be associated with these conditions. The invention further relates to kits encompassing reagents for assessing such markers, and diagnostic methods, uses and procedures for utilizing such markers. | 10-18-2012 |
| 20120220477 | GENETIC MARKERS ASSOCIATED WITH RISK OF DIABETES MELLITUS - The invention relates to variants that predispose to risk of type 2 diabetes, basal cell carcinoma and breast cancer. It has been discovered that certain genetic variants confer risk of these diseases when inherited from one parent, but not the other. The invention provides methods of disease management, including diagnostic methods, utilizing such parental origin effects. | 08-30-2012 |
| 20120208709 | GENETIC SUSCEPTIBILITY VARIANTS ASSOCIATED WITH CARDIOVASCULAR DISEASE - The invention relates to methods of diagnosing susceptibility to cardiovascular disease, including coronary artery disease, MI, abdominal aorta aneurysm, intracranial aneurysm restenosis and peripheral arterial disease, by assessing the presence or absence of alleles of certain polymorphic markers found to be associated with cardiovascular disease. The invention further relates to kits encompassing reagents for assessing such markers, and methods for assessing the probability of response to therapeutic agents and methods using such markers. | 08-16-2012 |
| 20120207729 | SUBSTITUTED BENZOAZOLE PDE4 INHIBITORS FOR TREATING PULMONARY AND CARDIOVASCULAR DISORDERS - The invention relates to substituted benzothiazoles, benzoxazoles—and their counterparts having pyridine and pyrimidine rings replacing the benzene ring—that are PDE4 inhibitors useful for treating stroke, myocardial infarct, and cardiovascular inflammatory conditions, to pharmaceutical compositions comprising these compounds, and to methods for the treatment of stroke, myocardial infarct, and cardiovascular inflammatory conditions in a mammal. The compounds have general formula I: | 08-16-2012 |
| 20120183522 | BIARYL PDE4 INHIBITORS FOR TREATING INFLAMMATORY, CARDIOVASCULAR AND CNS DISORDERS - The present invention relates to a genus of biaryl compounds containing at least one further ring. The compounds are PDE4 inhibitors useful for the treatment and prevention of stroke, myocardial infarct and cardiovascular inflammatory diseases and disorders. The compounds have general formula I: | 07-19-2012 |
| 20120149016 | Genetic Variants in the TCF7L2 Gene as Diagnostic Markers for Risk of Type 2 Diabetes Mellitus - Polymorphisms in the gene TCF7L2 are shown by association analysis to be a susceptibility gene for type II diabetes. Methods of diagnosis of susceptibility to diabetes, of decreased susceptibility to diabetes and protection against diabetes, are described, as are methods of treatment for type II diabetes. | 06-14-2012 |
| 20120122698 | Genetic Variants Predictive of Cancer Risk in Humans - The present invention discloses genetic variants that have been found to be predictive of risk of particular forms of cancer, in particular basal cell carcinoma and cutaneous melanoma. The invention provides methods of predicting risk of developing such cancers, and other methods pertaining to risk management of cancer utilizing such risk variants. The invention furthermore provides kits and computer systems for use in such methods. | 05-17-2012 |
| 20120021989 | GENETIC MARKERS FOR RISK MANAGEMENT OF ATRIAL FIBRILLATION AND STROKE - The invention relates to procedures and methods of determining a susceptibility to cardiac arrhythmia, including Atrial Fibrillation, Atrial Flutter and Stroke, by assessing the presence or absence of alleles at polymorphic markers found to be associated with risk of these conditions. The invention further relates to kits encompassing reagents for assessing such markers, and diagnostic 5 methods, uses and procedures for utilizing such susceptibility markers. | 01-26-2012 |
| 20110294673 | Genetic Variants for Breast Cancer Risk Assessment - The invention pertains to certain genetic variants that have been determined to be susceptibility variants of breast cancer. Methods of disease management, including diagnosing increased susceptibility to breast cancer, methods of predicting response to therapy and methods of predicting prognosis using such variants are described. The invention further relates to kits useful in the methods of the invention. | 12-01-2011 |
| 20110287946 | Genetic Variants Useful for Risk Assessment of Thyroid Cancer - The invention discloses genetic variants that have been determined to be susceptibility variants of thyroid cancer. Methods of disease management, including methods of determining susceptibility to thyroid cancer, methods of predicting response to therapy and methods of predicting prognosis of thyroid cancer using such variants are described. The invention further relates to kits useful in the methods of the invention. | 11-24-2011 |
| 20110269143 | Genetic Variants as Markers for Use in Urinary Bladder Cancer Risk Assessment, Diagnosis, Prognosis and Treatment - It has been discovered that certain genetic variants correlate with risk of urinary bladder cancer in humans. The invention relates to use of such variants in methods of disease management of urinary bladder cancer, including various diagnostic methods. | 11-03-2011 |
| 20110262901 | SUSCEPTIBILITY VARIANTS FOR PERIPHERAL ARTERIAL DISEASE AND ABDOMINAL AORTIC ANEURYSM - The present invention discloses certain genetic variants as susceptibility variants for peripheral arterial disease (PAD) and abdominal aortic aneurysm (AAA). The invention relates to risk management using such variants. The invention further relates to kits for use in risk assessment of PAD and AAA. | 10-27-2011 |
| 20110230366 | Genetic Variants Useful for Risk Assessment of Thyroid Cancer - The invention discloses genetic variants that have been determined to be susceptibility variants of thyroid cancer. Methods of disease management, including determining increased susceptibility to thyroid cancer, methods of predicting response to therapy and methods of predicting prognosis of thyroid cancer using such variants are described. The invention further relates to kits useful in the methods of the invention. | 09-22-2011 |
| 20110212855 | Genetic Variants Predictive of Cancer Risk - The invention discloses genetic variants that have been determined to be susceptibility variants of cancer. Methods of disease management, including determining increased susceptibility to cancer, methods of predicting response to therapy and methods of predicting prognosis of cancer using such variants are described. The invention further relates to kits useful in the methods of the invention. | 09-01-2011 |
| 20110117545 | GENETIC VARIANTS ON CHR2 AND CHR16 AS MARKERS FOR USE IN BREAST CANCER RISK ASSESSMENT, DIAGNOSIS, PROGNOSIS AND TREATMENT - The invention pertains to certain genetic variants on Chr2q14, Chr2q35 and Chr16q12 as susceptibility variants of breast cancer. Methods of risk assessment and diagnosis of increased and/or decreased susceptibility to breast cancer, using such variants are described. The invention further relates to kits for diagnosing a susceptibility to breast cancer. | 05-19-2011 |
| 20110091880 | SUSCEPTIBILITY VARIANTS FOR LUNG CANCER - The present invention discloses certain genetic variants as susceptibility variants for lung cancer. The invention relates to methods of risk assessment using such variants. The invention further relates to kits for use in risk assessment of lung cancer. | 04-21-2011 |
| 20110020320 | Genetic Variants Contributing to Risk of Prostate Cancer - It has been discovered that certain genetic markers are associated with risk of prostate cancer. The invention describes diagnostic applications for determining a susceptibilty to prostate cancer using such markers, including methods, uses, kits, and computer applications. | 01-27-2011 |
| 20110015081 | Genetic Variants on chr 5p12 and 10q26 as Markers for Use in Breast Cancer Risk Assessment, Diagnosis, Prognosis and Treatment - The invention pertains to certain genetic variants on Chr5p12 and Chr10q26 as susceptibility variants of breast cancer. Methods of disease management, including diagnosing increased and/or decreased susceptibility to breast cancer, methods of predicting response to therapy and methods of predicting prognosis using such variants are described. The invention further relates to kits useful in the methods of the invention. | 01-20-2011 |
| 20100216863 | Susceptibility Gene for Myocardial Infarction, Stroke, and PAOD; Methods of Treatment - Polymorphisms in the FLAP and LTA4H gene are shown by genetic association analysis to be susceptibility markers for myocardial infarction (MI) and ACS, as well as stroke and PAOD. Pathway targeting for treatment and diagnostic applications in identifying those who are at risk of developing MI, ACS, stroke or PAOD, in particular are described. The invention also provides methods of prophylaxis therapy for MI in human subjects having a race including black African ancestry by administering to the subject a composition comprising a therapeutically effective amount of MI therapeutic agent that inhibits leukotriene synthesis in vivo. The invention also provides for compositions comprising a leukotriene synthesis inhibitor and a statin and methods of using these compositions to reduce C-reactive protein in a human subject at risk of MI, ACS, stroke and/or PAOD. | 08-26-2010 |
| 20100160802 | Genetic Variants as Markers for Use in Diagnosis, Prognosis and Treatment of Eosinophilia, Asthma, and Myocardial Infarction - Polymorphic variants (e.g., certain alleles of polymorphic markers) that have been found to be associated with high blood eosinophil counts, conditions causative of eosinophilia (e.g., asthma, myocardial infarction), and/or hypertension are provided herein. Such polymorphic markers are useful for diagnostic purposes, such as in methods of determining a susceptibility, and for prognostic purposes, including methods of predicting prognosis and methods of assessing an individual for probability of a response to a therapeutic agent, as further described herein. Further applications utilize the polymorphic markers of the invention include, screening methods and genotyping methods. The invention furthermore provides related kits, computer-readable medium, and apparatus. | 06-24-2010 |
| 20100129799 | CANCER SUSCEPTIBILITY VARIANTS ON CHR8Q24.21 - A region on chromosome 8q24.21 has been demonstrated to play a major role in particular forms of cancer. It has been discovered that certain markers and haplotypes are indicative of a susceptibility to particular cancers, including prostate cancer. Diagnostic applications for identifying a susceptibility to cancer using these markers and haplotypes are described. | 05-27-2010 |
| 20100120045 | GENETIC VARIANTS USEFUL FOR RISK ASSESSMENTS OF CORONARY ARTERY DISEASE AND MYOCARDIAL INFARCTION - The invention relates to methods of risk assessment and diagnosis of susceptibility to coronary artery disease and myocardial infarction, by assessing the presence or absence of alleles of certain polymorphic markers found to be associated with coronary artery disease and myocardial infarction. The invention also relates to methods for use of such polymorphic markers for predicting drug response to drugs for treating cardiovascular disease, or for monitoring the effectiveness of such drugs. The invention further relates to kits encompassing reagents for use in these methods. | 05-13-2010 |
| 20100068705 | GENETIC SUSCEPTIBILITY VARIANTS ASSOCIATED WITH CARDIOVASCULAR DISEASE - The invention relates to methods of diagnosing susceptibility to cardiovascular disease, including coronary artery disease. MI, abdominal aorta aneurysm, intracranial aneurysm restenosis and peripheral arterial disease, by assessing the presence or absence of alleles of certain polymorphic markers found to be associates with cardiovascular disease. The invention further relates to kits encompassing reagents for assessing such markers, and methods for assessing the probability of response to therapeutic agents and methods using such markers. | 03-18-2010 |
| 20100047807 | GENETIC VARIANTS ASSOCIATED WITH PERIODIC LIMB MOVEMENTS AND RESTLESS LEGS SYNDROME - The present inventions discloses genetic markers and haplotypes that have been found to be associated with risk of Restless Legs Syndrome (RLS), Periodic Limb Movement Disorder (PLMD), and Periodic Limb Movements of Sleep (PLMS). Methods for determination of susceptibility of these disorders are disclosed using such markers, as are kits useful in such determination. | 02-25-2010 |
| 20090325163 | GENETIC MARKERS FOR RISK MANAGEMENT OF CARDIAC ARRHYTHMIA - The invention relates to procedure and methods of determining a susceptibility to cardiac arrhythmia, including Atrial Fibrillation, Atrial Flutter and Stroke, by assessing the presence or absence of alleles at polymorphic markers found to be associated with Atrial Fibrillation, Atrial Flutter and Stroke. The invention further relates to kits encompassing reagents for assessing such markers, and diagnostic methods, uses and procedures for utilizing such susceptibility markers. | 12-31-2009 |
| 20090324569 | BIARYL PDE4 INHIBITORS FOR TREATING INFLAMMATORY, CARDIOVASCULAR AND CNS DISORDERS - The present invention relates to a genus of biaryl compounds containing at least one further ring. The compounds are PDE4 inhibitors useful for the treatment and prevention of stroke, myocardial infarct and cardiovascular inflammatory diseases and disorders. The compounds have general formula I: | 12-31-2009 |
| 20090317799 | Variants at chr8q24.21 confer risk of cancer - A locus on chromosome 8q24.21 has been demonstrated to play a major role in particular forms of cancer. It has been discovered that certain markers and haplotypes are indicative of a susceptibility to particular cancers. Diagnostic applications for identifying susceptibilty to cancer are described. | 12-24-2009 |
| 20090291948 | SULFONAMIDE PERI-SUBSTITUTED BICYCLICS FOR OCCLUSIVE ARTERY DISEASE - Acyl sulfonamide, peri-substituted, fused bicyclic ring compounds useful for the treatment or prophylaxis of a prostaglandin-mediated disease or condition are disclosed. The compounds are of the general formula | 11-26-2009 |
| 20090275043 | Genetic variants in the TCF7L2 gene as diagnostic markers for risk of type 2 diabetes mellitus - Polymorphisms in the gene TCF7L2 are shown by association analysis to be a susceptibility gene for type II diabetes. Methods of diagnosis of susceptibility to diabetes, of decreased susceptibility to diabetes and protection against diabetes, are described, as are methods of treatment for type II diabetes. | 11-05-2009 |
| 20090163462 | BIARYL SUBSTITUTED HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION - The present invention relates to a chemical genus of biaryl substituted heterocycle inhibitors of LTA4H (leukotriene A4 hydrolase) useful for the treatment and prevention and prophylaxis of inflammatory diseases and disorders. The compounds have general formula Ψ: | 06-25-2009 |
| 20090136473 | BIARYL PDE4 INHIBITORS FOR TREATING PULMONARY AND CARDIOVASCULAR DISORDERS - The present invention relates to a genus of biaryl compounds containing at least one further ring. The compounds are PDE4 inhibitors useful for the treatment and prevention of stroke, myocardial infarct and cardiovascular inflammatory diseases and disorders. The compounds have general formula Ia, Ib, Ic or Id: | 05-28-2009 |
| 20090131530 | 4- (OR 5-) SUBSTITUTED CATECHOL DERIVATIVES - Compounds of the formula: | 05-21-2009 |
| 20090130077 | SUBSTITUTED BENZOAZOLE PDE4 INHIBITORS FOR TREATING INFLAMMATORY, CARDIOVASCULAR AND CNS DISORDERS - The invention relates to substituted benzothiazoles, benzoxazoles—and their counterparts having pyridine and pyrimidine rings replacing the benzene ring—that are PDE4 inhibitors useful for treating stroke, myocardial infarct, and cardiovascular inflammatory conditions, to pharmaceutical compositions comprising these compounds, and to methods for the treatment of stroke, myocardial infarct, and cardiovascular inflammatory conditions in a mammal. The compounds have general formula I: | 05-21-2009 |
| 20090130076 | SUBSTITUTED BENZOAZOLE PDE4 INHIBITORS FOR TREATING PULMONARY AND CARDIOVASCULAR DISORDERS - The invention relates to substituted benzothiazoles, benzoxazoles—and their counterparts having pyridine and pyrimidine rings replacing the benzene ring—that are PDE4 inhibitors useful for treating stroke, myocardial infarct, and cardiovascular inflammatory conditions, to pharmaceutical compositions comprising these compounds, and to methods for the treatment of stroke, myocardial infarct, and cardiovascular inflammatory conditions in a mammal. The compounds have general formula I: | 05-21-2009 |
| 20090030037 | Sustained Release Formulation and Dosing Schedules of Leukotriene Synthesis Inhibitor for Human Therapy - The invention relates to materials and methods for therapy to inhibit the production of leukotrienes, and therapeutic and prophylactic applications thereof. | 01-29-2009 |
